80022730: Macula 2010

Click here for a text version of the brochure
Text version of brochure

ACCREDITATION STATEMENT The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. CREDIT DESIGNATION STATEMENT The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 8.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Description:
Over the past several years, there is a growing body of medical evidence that demonstrates a clear biologic rationale for targeting vascular endothelial growth factors (VEGFs) in the treatment of neovascular AMD, diabetic retinopathy, and venous occlusive disease. This area of investigation is relatively new, and most ophthalmologists are not aware of the myriad growth factors and their potential role in AMD, diabetic retinopathy, and venous occlusive disease. There is a need to understand these new tools for assessing outcomes and also to understand data based on visual acuity loss measurements from clinical trials of these new agents. Furthermore, it is important to review the role of imaging studies, especially optical coherence tomography, in the management of these ocular conditions. Thus, this new therapeutic approach for neovascular AMD, diabetic retinopathy, and venous occlusive disease has been evolving over the past three years and is an area of great interest both to ophthalmologists who treat these diseases and to those who refer these cases for further management. Presentations will be chosen to emphasize new information on the use of VEGF inhibitors and pharmacologic agents in the management of these diseases. In addition, cases will be chosen which highlight new information being reported by the Diabetic Retinopathy Clinical Research Network and other randomized clinical trials.

Objectives:
After attending this activity, the participant will demonstrate the ability to:
• Recognize the role of angiogenesis in AMD and evaluate various treatment intervals for eyes undergoing therapy with VEGF inhibitors.
• Evaluate recent clinical studies evaluating treatments for macular edema due to retinal vein occlusion.
• Recognize the role of spectral domain OCT in the management of eyes with neovascular AMD.
• Review the current and emerging therapies for treating non-neovascular AMD.
• Summarize evidence of the role of ranibizumab for diabetic macular edema.
• Determine which patients are appropriate for laser treatment in eyes with diabetic macular edema.
• Diagnose choroidal melanoma and review treatment options.
• Be familiar with the management of diabetic retinopathy and the new results from the clinical trials conducted by the Diabetic Retinopathy Clinical Research Network.

Talks

Policy On Speaker And Provider Disclosure

It is the policy of the Johns Hopkins University School of Medicine that the speaker and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made in the activity handout materials.